NRAS and glioma: Studying an extended tumor cell line panel (including 11 different human melanoma cell lines with differential BRAF or NRAS mutations, as well as a murine melanoma cell line and two human glioma cell lines) provided evidence that iHsp90 treatment may be effective on different neural crest-derived tumors.